Treatment of candidemia with echinocandins: data on hospital resource use from a real world setting.
| Autor: | Wade RL; Cerner LifeSciences, Culver City, CA 90230, USA. rolin.wade@cerner.com, Chaudhari P, Campbell RS, Hays HD, Nathanson BH, Yi J, Horn D |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of medical economics [J Med Econ] 2012; Vol. 15 (6), pp. 1130-8. Date of Electronic Publication: 2012 Jul 13. |
| DOI: | 10.3111/13696998.2012.708690 |
| Abstrakt: | Objective: Real-world data on patients treated with echinocandins for candidemia are limited. This study examined the effect of three echinocandin-based treatment regimens on resource utilization in patients with Candida infection. Research Design and Methods: A retrospective cohort study of patients hospitalized between 2005 and 2010 with a blood culture positive for Candida. Length of stay (LOS) following AF initiation (post-AF LOS) and total days with AF treatment were compared in patients treated with three different echinocandin regimens: patients with echinocandin only, patients who received fluconazole prior to an echinocandin (fluconazole-echinocandin), and patients who received an echinocandin prior to fluconazole (echinocandin-fluconazole). Generalized linear models were used to adjust for confounders. Results: A total of 647 patients met inclusion criteria. Patients treated with echinocandin only were more acutely ill, having more organ dysfunction and sepsis. Unadjusted post-AF LOS was significantly greater in the groups that received both echinocandin and fluconazole (mean, 13.1 days for echinocandin-only vs 25.5 and 21.2 days for fluconazole-echinocandin and echinocandin-fluconazole groups, respectively, p<0.001). These groups also had a higher total number of days with AF orders. These differences remained after multivariate adjustment and in survivor-only analyses. Compared with echinocandin-only treatment, the average marginal effect of fluconazole-echinocandin and echinocandin-fluconazole regimens were associated with significantly longer adjusted post-AF LOS (by 7.2 days and 9.3 days, respectively, p<0.001) and significantly more adjusted total AF days (by 5.3 days for fluconazole-echinocandin and 6.5 days for echinocandin-fluconazole patients, p<0.001). Limitations included lack of visibility to specific reasons for therapy changes. Conclusions: Fluconazole before or after echinocandin was associated with significantly greater resource utilization than echinocandin use alone. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|